q-1802

Q-1802 is a humanized bispecific antibody that targets both Claudin 18.2 (CLDN18.2), a tumor-specific antigen, and the immune checkpoint programmed death-ligand 1 (PD-L1). Developed by QureBio, it is designed to treat advanced or metastatic solid tumors, particularly those with CLDN18.2 expression such as gastric, pancreatic, biliary tract cancers, and other gastrointestinal malignancies[1][4][5]. The drug works by recruiting multiple immune mechanisms to kill tumor cells—including antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP)—while also blocking PD-L1 to enhance natural and adaptive immunity[4][8]. Clinical trials have shown promising anti-tumor activity with an objective response rate of up to 70% in certain patient groups[4]. Q-1802 has demonstrated a favorable safety profile in early-phase studies[3][5].

Other names

anti-PD-L1/Claudin18.2 bispecific antibody Q-1802